UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 29, 2015
Viking Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-37355 | 46-1073877 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
11119 North Torrey Pines Road, Suite 50, San Diego, CA 92037
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (858) 550-7810
N/A
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On May 29, 2015, Viking Therapeutics, Inc. (the “Company”) issued a press release announcing that the underwriters for its recently announced initial public offering exercised in full their option to purchase an additional 450,000 shares of the Company’s common stock. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
99.1 Press Release, dated May 29, 2015, issued by Viking Therapeutics, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Viking Therapeutics, Inc. | ||
| By: | /s/ Brian Lian, Ph.D. | |
| Brian Lian, Ph.D. | ||
| President and Chief Executive Officer | ||
Date: May 29, 2015
INDEX TO EXHIBITS
| Number |
Description | |
| 99.1 | Press Release, dated May 29, 2015, issued by Viking Therapeutics, Inc. | |